Malignant peripheral nerve sheath tumor (MPNST), which originates in Schwann cells, is uncommon in the head and neck. Th ese highly aggressive sarcomas are characterized by local recurrence and distant metastasis. Many are associated with neurofibromatosis type 1; the survival rate in such cases is poorer than the rate associated with tumors that arise de novo. Hypercellularity and pleomorphism are cardinal microscopic features. Immunohistochemical staining is widely used to determine S-100 positivity and a Ki-67 score, either of which may establish the prognosis. We present a case of MPNST of the neck that arose in a 17-year-old girl, who was also found to have a parapharyngeal neurofi broma. Th e cervical mass was excised (intraoperative complications precluded removal of the parapharyngeal mass) and radiotherapy was administered, but the patient experienced a recurrence within 2 months. Another surgery was performed, and this time both tumors were removed. At 1 year of follow-up, the patient was without disease, but in postoperative year 2, she died from complications of a cervical recurrence and mediastinal metastasis.
Introduction
Malignant peripheral nerve sheath tumor (MPNST)-also known as malignant schwannoma, neurofi brosarcoma, malignant neurilemmoma, and neurogenic sarcoma-is derived from Schwann cells. Th is tumor is usually found in the retroperitoneal area and lower extremities; it is uncommon in the head and neck. 1, 2 MPNST accounts for 5 to 10% of all soft -tissue sarcomas. [1] [2] [3] Many of these tumors are associated with neurofi bromatosis type 1 (NF-1). 1, 3 Malignant schwannomas are highly aggressive, and local invasion, recurrence, and metastasis are common. 2, 4 However, regional lymph node involvement is rare. 1, 3 Local recurrence rates have been reported to be in the range of 38 to 45%, and distant metastasis rates in the range of 40 to 80%. 3, 5 Th e most common routes of distant metastasis are hematogenous and perineural. Th e lung, liver, subcutaneous tissues, and bone are the most common sites of metastasis. 1, 3 Th e treatment of choice for MPNST of the head and neck is radical resection followed by radiation therapy. 6 We present a new case of MPNST of the neck.
Case report
A 17-year-old girl was admitted to our ENT department with a complaint of left -sided neck swelling of 6 months' duration. Th e swelling was mild initially, but its size had rapidly increased over the preceding 2 months. Th e patient was also experiencing some diffi culty swallowing, but no dyspnea had been noted, even on exertion. She had been previously diagnosed with autism, mental retardation, and multiple café au lait spots over the chest and extremities. Prior to her presentation, she had undergone cranial magnetic resonance imaging (MRI), which had detected a parapharyngeal-space mass, but no cervical mass.
On examination, the neck mass measured approximately 5 × 5 cm along the upper half of the left side of the neck. In addition, an oral examination revealed the presence of a bulging mass over the left side of the soft palate and tonsillar fossa. Th e previously obtained MRI sacrifi ced, but the carotid system was kept intact. On histopathology, the cervical mass was diagnosed as an MPNST and the parapharyngeal mass as a neurofi broma. Th e immunohistochemical characteristics of the MPNST were similar to those of the resected material obtained during the fi rst operation.
No complications were observed during the postoperative period except left -sided vocal fold paralysis with associated aspiration, which was expected, and left -sided Horner syndrome. At the 1-year follow-up, the patient exhibited no evidence of local recurrence or distant metastasis. However, during the second postoperative year, she was admitted with a cervical recurrence and a mediastinal metastasis, and she died of respiratory insuffi ciency soon thereaft er.
Discussion
Approximately 40 to 50% of all cases of MPNST arise in patients with preexisting NF-1; the risk of MPNST in patients with NF-1 ranges from 2 to 29%. 1, 3 Survival is showed that the parapharyngeal mass was 5 cm in diameter and that it had obliterated the oropharynx; these fi ndings suggested a probable diagnosis of a neurogenic tumor (fi gure 1). Th e patient's parents refused to allow her to undergo another MRI to evaluate the cervical mass. No evidence of NF-1 was found on neurologic and genetic investigations.
Aft er the risks of surgery were explained to the parents, the patient was operated on under general anesthesia. A cervical approach was chosen, and a left -sided oblique neck incision was made. Th e mass was found to be medial and deep to the carotid bifurcation. Aft er the carotid system and the vagus nerve were retracted laterally, the mass was identifi ed, completely skeletonized, and removed en bloc. Th e tumor had not originated in the vagus nerve or any other cranial nerve coursing through the neck.
Next, the parapharyngeal mass was explored medial to the mandible, but it could not be excised because of the onset of bradycardia that was unresponsive to medication. Surgery was then halted, and the surgical site was closed. Th e resected cervical mass was sent for histopathologic examination, which yielded a diagnosis of MPNST. Approximately 50% of the tumor cells were positive for S-100 protein, and the Ki-67 score was 20 to 30%.
Since the recommended treatment of MPNST includes adjuvant radiotherapy, the patient was referred to the radiation oncology department, where she underwent radiotherapy under sedation for 5 weeks. However, at the end of that period, physical examination revealed a 5-cm recurrence of the mass on the left side of the neck. Th is time the parents did authorize MRI, and it revealed that not only was there a cervical recurrence, but the left parapharyngeal mass apparently had not regressed at all; it measured 5 × 5.5 × 3 cm (fi gure 2). Th e recurrent cervical mass measured 5.5 × 4.5 × 3 cm; it was located just inferior to the parapharyngeal mass, and it had displaced the carotid system posterolaterally (fi gure 2).
The patient was taken back to the operating room and placed under general anesthesia. Th is time, it was possible to remove both the cervical and parapharyngeal masses. Th e vagus nerve and the adventitia of the carotid system were both found to be invaded; the nerve was 
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reported to be poorer in patients with associated NF-1. 2, 5 Our patient had a poor prognosis, although a diagnosis of NF-1 was not confi rmed. Previous radiation therapy is considered to be a risk factor for MPNST. 7 MPNST is uncommon in the head and neck region, accounting for 10 to 12% of all cases according to Patil et al 1 and for 9 to 14% by Lee et al. 2 Reported head and neck sites have included the oral cavity, paranasal sinuses, parapharyngeal space, mandibular area, and thyroid gland. [1] [2] [3] [4] 6, 8 Patients with parapharyngeal tumors may exhibit few if any symptoms and remain undiagnosed until the tumor's growth becomes evident. 2 Th e most common presenting symptom of cervical MPNST is a neck mass, with or without pain. 4, 9 Most MPNSTs appear to arise in adults between the ages of 20 and 50 years. [1] [2] [3] Microscopically, MPNSTs are characterized by hypercellularity with spindle-shaped cells and signifi cant nuclear pleomorphism, as was seen in our case. 3 Immunohistochemical analysis reveals S-100 positivity in most MPNSTs (50 to 70%). 5 S-100 protein is a known marker for neuroectodermal origin. Ki-67 immunoreactivity, which is used to evaluate the tumor growth fraction, has been reported in 5 to 65% of MPNSTs. 5 In our case, S-100 positivity was seen in 50% of the neoplastic cells, and the Ki-67 score was relatively high (20 to 30%).
Wide local resection followed by adjuvant radiotherapy is generally considered to be the best treatment option for head and neck MPNST. [2] [3] [4] Stark et al reported that adjuvant chemotherapy has a poor eff ect on prognosis. 5 Patil et al reported that MPNST was resistant to both radiotherapy and chemotherapy. 1 Th erefore, the role of radiotherapy has become controversial.
Five-year survival for patients with MPNST has been reported to be in the range of 30 to 66% by Lee et al 2 and 15 to 35% by Pfeiff er et al. 3 Watanabe et al found that a Ki-67 score of greater than 25% was associated with decreased survival. 10 
